^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + tigozertinib (BLU-945) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1467-BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)
Published date:
03/10/2021
Excerpt:
In vivo activity was also evaluated in an intracranial implantation model using luciferase-expressing YU-1097 patient-derived-cells harboring EGFRex19del/T790M/C797S resistance mutations...In addition, combination of BLU-945 with osimertinib showed enhanced antitumor activity compared with single-agent treatment in the EGFRex19del/T790M/C797S PDX model.
